Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 64

1.
2.

[Prostate cancer: the evidence weighs against screening].

Hill C, Laplanche A.

Presse Med. 2010 Sep;39(9):859-64. doi: 10.1016/j.lpm.2010.04.001. Epub 2010 May 24. French.

PMID:
20494543
4.

Screening for prostate cancer: an update.

Bryant RJ, Hamdy FC.

Eur Urol. 2008 Jan;53(1):37-44. Epub 2007 Aug 27. Review.

PMID:
17826892
5.
6.

Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force.

Harris R, Lohr KN.

Ann Intern Med. 2002 Dec 3;137(11):917-29. Review.

PMID:
12458993
7.

The Japanese guideline for prostate cancer screening.

Hamashima C, Nakayama T, Sagawa M, Saito H, Sobue T.

Jpn J Clin Oncol. 2009 Jun;39(6):339-51. doi: 10.1093/jjco/hyp025. Epub 2009 Apr 4.

8.

Screening for prostate cancer: a Cochrane systematic review.

Ilic D, O'Connor D, Green S, Wilt T.

Cancer Causes Control. 2007 Apr;18(3):279-85. Epub 2007 Jan 6. Review.

PMID:
17206534
9.

Update on screening and early detection of prostate cancer.

Otto SJ, de Koning HJ.

Curr Opin Urol. 2004 May;14(3):151-6. Review.

PMID:
15069305
10.

Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force.

Lin K, Lipsitz R, Miller T, Janakiraman S; U.S. Preventive Services Task Force.

Ann Intern Med. 2008 Aug 5;149(3):192-9. Review.

PMID:
18678846
11.

Smarter screening for prostate cancer: for the few, not the many? A stratified approach based on baseline risk.

Sooriakumaran P.

Expert Rev Anticancer Ther. 2011 Feb;11(2):169-72. doi: 10.1586/era.10.233.

PMID:
21342035
12.

Should prostate-specific antigen screening be offered to asymptomatic men?

van Vugt HA, Bangma CH, Roobol MJ.

Expert Rev Anticancer Ther. 2010 Jul;10(7):1043-53. doi: 10.1586/era.10.64. Review.

PMID:
20645694
13.

Short-term effects of population-based screening for prostate cancer on health-related quality of life.

Essink-Bot ML, de Koning HJ, Nijs HG, Kirkels WJ, van der Maas PJ, Schröder FH.

J Natl Cancer Inst. 1998 Jun 17;90(12):925-31.

14.

Controversies in prostate cancer screening.

Murphy AM, McKiernan JM, Olsson CA.

J Urol. 2004 Nov;172(5 Pt 1):1822-4.

PMID:
15540729
15.

Screening for prostate cancer.

Schröder FH.

Urol Clin North Am. 2003 May;30(2):239-51, viii. Review.

PMID:
12735501
16.

Prostate cancer: to screen or not to screen.

Bailey SJ, Brewster SF.

Arch Esp Urol. 2011 Jun;64(5):406-18. Review. English, Spanish.

PMID:
21705812
17.

Screening for prostate cancer: updated experience from the Tyrol study.

Horninger W, Berger A, Pelzer A, Klocker H, Oberaigner W, Schönitzer D, Severi G, Robertson C, Boyle P, Bartsch G.

Can J Urol. 2005 Feb;12 Suppl 1:7-13; discussion 92-3.

PMID:
15780158
18.
19.

The clinical effectiveness and cost-effectiveness of computed tomography screening for lung cancer: systematic reviews.

Black C, Bagust A, Boland A, Walker S, McLeod C, De Verteuil R, Ayres J, Bain L, Thomas S, Godden D, Waugh N.

Health Technol Assess. 2006 Jan;10(3):iii-iv, ix-x, 1-90. Review.

20.

Randomized trial results did not resolve controversies surrounding prostate cancer screening.

Hoffman RM.

Curr Opin Urol. 2010 May;20(3):189-93. doi: 10.1097/MOU.0b013e3283383b55. Review.

PMID:
20224414
Items per page

Supplemental Content

Write to the Help Desk